Dr. Rebecca Lumsden, Head of Science Policy at the Association for the British Pharmaceutical Industry (ABPI), has been named as a ‘Rising Star’ in the BioBeat 50 Movers and Shakers in BioBusiness 2016.
The annual report, authored by Miranda Weston-Smith, identifies 50 women from across biotech that are deemed extraordinary leaders making an impact in a wide range of industry and research areas.
Dr Rebecca Lumsden, ABPI Head of Science Policy, has been named a 'Rising Star' in biotech
Dr. Lumsden has been recognised for her work at the ABPI which ranges from rare diseases – supporting the implementation of the UK Strategy for Rare Diseases - precision medicine, and tackling antimicrobial resistance – a hot topic following the publication of the Review on Antimicrobial Resistance earlier this year – to maintaining the excellence of the UK's science base more generally.
She was a post-doctoral scientist prior to pursuing a career in policy, and studied for her PhD in cancer cell signalling at Fitzwilliam College, University of Cambridge. In response to being named in this year's BioBeat report, Dr. Rebecca Lumsden said:
"I am honoured to be named as a Rising Star in this year's report amongst so many inspiring leaders in our field. Campaigns like this play a vital role in recognising the important roles women play within the industry and in academia, and I think it is important to tackle gender inequality across STEM and inspire the next generation.
This is an exciting time for UK Life Sciences and organisations, like BioBeat, provide opportunities to build relationships across the sector, to share ideas and solutions, and drive the innovation that is central to the Life Sciences sector. It's inspiring to see a move towards greater collaboration across industry and academia and publications, like the 50 Movers and Shakers in BioBusiness, are critical to starting the conversations that drive this open innovation environment – an environment which has helped support my career and which I hope will continue to let others in the industry flourish."
The report has been launched ahead of the BioBeat event in Cambridge on Wednesday 16 November, which provides a platform for entrepreneurial leaders in biobusiness to discuss innovation in the sector. Providing the foreword for the report, ABPI President John Kearney celebrated women in STEM as well as the implication their work has on the future of British science:
"50 Movers and Shakers in BioBusiness 2016 is a well-deserved celebration of the dedicated women who are changing the face and future of healthcare.
Congratulations to each of these 50 women. We know there is a need for female role models in this industry and these women are an excellent inspiration for the next generation of Life Science leaders. Each one of them are working towards a brighter, healthier future, committed to making the greatest different to people's lives – through improving their health."
ABPI Press Office Email: email@example.com Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441 Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.